Growth hormone response to the hypothalamic somatostatinergic activity in acromegalic patients

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 8, 1997, Pages 2492-2496

  Yang, I ^a   Park, S ^a   Woo, J ^a   Kim, S ^a   Kim, J ^a   Kim, Y ^a   Choi, Y ^a  

^a Kyung Hee University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GONADORELIN; GROWTH HORMONE; OCTREOTIDE; PROTIRELIN; RELEFACT; SOMATOSTATIN; THYROTROPIN;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GROWTH HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; HYPOTHALAMUS; INTRAVENOUS DRUG ADMINISTRATION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTIRELIN TEST; THYROTROPIN RELEASE; TUMOR VOLUME;

ACROMEGALY; ADENOMA; ADULT; FEMALE; GLUCOSE; GONADOTROPIN-RELEASING HORMONE; HUMAN GROWTH HORMONE; HUMANS; HYPOTHALAMUS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; SOMATOSTATIN; THYROTROPIN; THYROTROPIN-RELEASING HORMONE;

EID: 0030743048     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.8.2492     Document Type: Article

References (32)

1. Patel YC, Krishna R, Reichlin S. 1977 Somatostatin in human cerebrospinal fluid. N Engl J Med. 296:529-533.
2. Merola B, Colao A, Cataldi M, et al. 1992 Serum thyrotropin response to combined arginine and thyrotropin-releasing hormone administration provides evidence for an altered somatostatinergic tone in acromegaly. Horm Res. 37:7-13.
3. Attanasio R, Cozzi R, Oppizzi G, et al. 1995 Persistence of somatostatinergic tone in acromegaly. Eur J Endocrinol. 132:27-31.
4. Masuda A, Shibasaki M, Nakamura T, et al. 1985 The effect of glucose on growth hormone(GH)-releasing hormone-mediated GH secretion in man. J Clin Endocrinol Metab. 60:523-526.
5. Sharp PS, Foley K, Chahal P, Kohner EM. 1984 The effect of plasma glucose on the growth hormone response to human pancreatic growth hormone releasing factor in normal subjects. Clin Endocrinol (Oxf). 20:497-501.
6. Penalva A, Burguera B, Casabiell X, Tresguerres JAF, Dieguez C, Casanueva FF. 1989 Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone releasing hormone induced growth hormone secretion in man: suggesting that glucose acts through hypothalamic release of somatostatin. Neuroendocrinology. 49:551-554.
7. Besser GM, Mortimer CH, Carr D, et al. 1974 Growth hormone release inhibiting hormone in acromegaly. Br Med J. 1:352-355.
8. Yen SSC, Siler TM, DeVane GW. 1974 Effect of somatostatin in patients with acromegaly. N Engl J Med. 290:935-938.
9. Hanew K, Kokubun M, Sasaki A, Mouri T, Yoshinaga K. 1980 The spectrum of pituitary growth hormone responses to pharmacological stimuli in acromegaly. J Clin Endocrinol Metab. 51:292-297.
10. Pieters GFFM, Romeijn JE, Smals AGH, Kloppenborg PWC. 1982 Somatostatin sensitivity and growth hormone responses to releasing hormones and bromocriptine in acromegaly. J Clin Endocrinol Metab. 54:942-948.
11. Oppizzi G, Botalla L, Verde G, Cozzi R, Liuzzi A, Chiodini P. 1980 Homogeneity in growth hormone lowering effect of dopamine and somatostatin in acromegaly. J Clin Endocrinol Metab. 51:616-619.
12. Plewe G, Beyer J, Krause U, Neufeld M, del Pozo E. 1984 Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet. 2:782-784.
13. Lamberts SWJ, Uitterlinden P, Verschoor L, van Dongen KJ, del Pozo E. 1985 Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med. 313:1576-1580.
14. Barkan AL, Kelch RP, Hopwood NJ, Beitins IZ. 1988 Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995. J Clin Endocrinol Metab. 66:16-23.
15. Ho KY, Weissberger AJ, Marbach P, Lazarus L. 1990 Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Ann Intern Med. 112:173-181.
16. Wagenaar AH, Harris AG, van der Lely AJ, Lamberts SW. 1991 Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly. Acta Endocrinol (Copenh). 125:637-642.
17. Yang IM, Woo JT, Kim SW, Kim JW, Kim YS, Choi YK. 1995 Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue. Clin Endocrinol (Oxf). 42:295-301.
18. Yang I, Woo J, Kim S, Kim J, Kim Y, Choi Y. 1996 Suppression of TRH-stimulated TSH secretion by glucose-induced hypothalamic somatostatin release. Horm Metab Res. 28:553-556.
19. Yang I, Park S, Ryu M, Kim S, Kim J, Kim Y, et al. 1996 Characteristics of gsp-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients. Eur J Endocrinol. 134:720-726.
20. Greeman Y, Tordjman K, Kisch E, Razon N, Ouaknine G, Stern N. 1995 Relative sparing of anterior pituitary function in patients with growth hormone-secreting macroadenomas: comparison with nonfunctioning macroadenomas. J Clin Endocrinol Metab. 80:1577-1583.
21. Siler TM, Yen SSC, Vale W, Guillemin R. 1974 Inhibition by somatostatin of the release of TSH induced in man by thyrotropin-releasing factor. J Clin Endocrinol Metab. 38:742-745.
22. Williams TC, Kelijman M, Cerlin WC, Downs TR, Frohman A. 1988 Differential effects of somatostatin (SRIH) and a SRIH analog, SMS 201-995, on the secretion of growth hormone and thyroid stimulating hormone in man. J Clin Endocrinol Metab. 66:39-45.
23. Samuels MH, Henry P, Ridgway EC. 1992 Effects of dopamine and somatostatin on pulsatile pituitary glycoprotein secretion. J Clin Endocrinol Metab. 74:217-222.
24. Spoudeas HA, Matthews DR, Brook CG, Hindmarsh PC. 1992 The effect of changing somatostatin tone on the pituitary growth hormone and thyroid-stimulating hormone responses to their respective releasing factor stimuli. J Clin Endocrinol Metab. 73:453-458.
25. Yang I, Woo J, Kim S, Kim J, Kim Y, Choi Y. 1995 Combined pyridostigminethyrotrophin-releasing hormone test for the evaluation of hypothalamic somatostatinergic activity in healthy normal men. Eur J Endocrinol. 133:457-462.
26. Lamberts SWJ, Krenning EP, Reubi JC. 1991 The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev. 12:450-482.
27. Liebow C, Reilly V, Serrano M, Schally AV. 1989 Somatostatin analogues inhibit growth of pancreatic cancer by stimulating a tyrosine phosphatase. Proc Natl Acad Sci USA. 86:2003-2007.
28. Pan MG, Florio T, Stork PJS. 1992 G protein activation of a hormone-stimulated phosphatase in human tumor cells. Science. 256:1215-1217.
29. Barkan AL, Kelch RP, Hopwood NJ, Beitins IZ. 1988 Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995. J Clin Endocrinol Metab. 66:16-23.
30. Patel YC, Srikant CB. 1944 Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology. 135:2814-2817.
31. Panetta R, Greenwood MT, Warszynska A, et al. 1994 Molecular cloning, functional characterization, and chromosomal localization of a human somatostatin receptor (somatostatin receptor type 5) with preferential affinity for somatostatin-28. Mol Pharmacol. 45:417-427.
32. Spada A, Arosio M, Bochicchio D, et al. 1990 Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab. 71:1421-1426.